This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
Subjects with intracranial lesions undergoing surgical removal as their standard of care will be eligible. These may include subjects status post chemotherapy and/or radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are deemed to be candidates for resection.
Subject age ≥ 18 years.
Chemistry Panel - Potassium, BUN (or urea), and Creatinine
CBC with differential - WBC, including ANC, hemoglobin, hematocrit, and platelet count
Had a myocardial infarction, cerebrovascular accident, or uncontrolled chronic heart failure within 6 months prior to enrollment.
History of infusion reactions to any monoclonal antibody therapies.
Women who are currently pregnant or breastfeeding.
Participants presenting with a baseline QTcF interval > than 480 milliseconds.
Eben Rosenthal
Lead sponsor
Vanderbilt-Ingram Cancer Center
Sponsor institution